Scleroderma: therapeutic options.
Although the cause of scleroderma remains elusive, pharmacologic advances and increased understanding of the pathophysiology of this disease provide therapeutic options. Therapy usually addresses the fibrotic, vascular, or immunologic alterations, but general measures can be helpful and should not be overlooked.
D000527:Alprostadil; D002216:Captopril / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use; D006118:Griseofulvin / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D010956:Plasmapheresis; D011458:Prostaglandins E / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000188:drug therapy / Q000628:therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D011458:Prostaglandins E; D014665:Vasodilator Agents; D006118:Griseofulvin; D010672:Phenytoin; D002216:Captopril; D000527:Alprostadil; D010396:Penicillamine; D009543:Nifedipine; D003078:Colchicine